{"id":"https://openalex.org/W4361939654","doi":"https://doi.org/10.1158/1078-0432.22481079","title":"Supplemental Figure 1 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma","display_name":"Supplemental Figure 1 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361939654","doi":"https://doi.org/10.1158/1078-0432.22481079"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22481079","doi":"https://doi.org/10.1158/1078-0432.22481079","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22481079","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplemental_Figure_1_from_Long-term_Follow-up_and_Correlative_Analysis_of_Two_Phase_II_Trials_of_Rituximab_and_Lenalidomide_Followed_by_Continuous_Lenalidomide_in_Untreated_and_Relapsed_Refractory_Indolent_Lymphoma/22481079/1/files/39932589.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplemental_Figure_1_from_Long-term_Follow-up_and_Correlative_Analysis_of_Two_Phase_II_Trials_of_Rituximab_and_Lenalidomide_Followed_by_Continuous_Lenalidomide_in_Untreated_and_Relapsed_Refractory_Indolent_Lymphoma/22481079/1/files/39932589.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045079164","display_name":"Joseph M. Tuscano","orcid":"https://orcid.org/0000-0002-0522-1406","observed_orcids":["https://orcid.org/0000-0002-0522-1406"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph M. Tuscano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054146743","display_name":"Christina Poh","orcid":"https://orcid.org/0000-0003-3120-712X","observed_orcids":["https://orcid.org/0000-0003-3120-712X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christina Poh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066543172","display_name":"Paul R. Kaesberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Kaesberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084956764","display_name":"Guillaume Luxardi","orcid":"https://orcid.org/0000-0003-3338-0583","observed_orcids":["https://orcid.org/0000-0003-3338-0583"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guilluame Luxardi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3338-0583","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032164345","display_name":"Alexander A. Merleev","orcid":"https://orcid.org/0000-0002-5735-7233","observed_orcids":["https://orcid.org/0000-0002-5735-7233","https://orcid.org/0000-0002-5031-4775"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexander Merleev","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5735-7233","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076958813","display_name":"Alina I. Marusina","orcid":"https://orcid.org/0000-0002-2352-315X","observed_orcids":["https://orcid.org/0000-0002-2352-315X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alina Marusina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060558335","display_name":"Ann M. Brunson","orcid":"https://orcid.org/0000-0001-5308-9457","observed_orcids":["https://orcid.org/0000-0001-5308-9457"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann Brunson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Aaron Rosenberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aaron Rosenberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068133376","display_name":"Brian Andrew Jonas","orcid":"https://orcid.org/0000-0002-4921-5809","observed_orcids":["https://orcid.org/0000-0002-4921-5809"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Jonas","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4921-5809","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5030729248","display_name":"Emanual Michael Maverakis","orcid":"https://orcid.org/0000-0002-6294-6294","observed_orcids":["https://orcid.org/0000-0002-6294-6294"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emanual Maverakis","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6294-6294","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.010700000450015068,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9369999766349792},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/indolent-lymphoma","display_name":"indolent lymphoma","score":0.9589999914169312},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9049999713897705},{"id":"https://openalex.org/keywords/plasma-cytokine-levels","display_name":"plasma cytokines","score":0.8429999947547913},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.5230000019073486}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9370027184486389},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7442624568939209},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6893836259841919},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5788171887397766},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5387628078460693},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5108413100242615},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4373226463794708},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3967415392398834},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3614468574523926},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.17046386003494263},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07765403389930725},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22481079","doi":"https://doi.org/10.1158/1078-0432.22481079","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22481079","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplemental_Figure_1_from_Long-term_Follow-up_and_Correlative_Analysis_of_Two_Phase_II_Trials_of_Rituximab_and_Lenalidomide_Followed_by_Continuous_Lenalidomide_in_Untreated_and_Relapsed_Refractory_Indolent_Lymphoma/22481079/1/files/39932589.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22481079.v1","doi":"https://doi.org/10.1158/1078-0432.22481079.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22481079.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22481079","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplemental_Figure_1_from_Long-term_Follow-up_and_Correlative_Analysis_of_Two_Phase_II_Trials_of_Rituximab_and_Lenalidomide_Followed_by_Continuous_Lenalidomide_in_Untreated_and_Relapsed_Refractory_Indolent_Lymphoma/22481079","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22481079","doi":"https://doi.org/10.1158/1078-0432.22481079","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22481079","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplemental_Figure_1_from_Long-term_Follow-up_and_Correlative_Analysis_of_Two_Phase_II_Trials_of_Rituximab_and_Lenalidomide_Followed_by_Continuous_Lenalidomide_in_Untreated_and_Relapsed_Refractory_Indolent_Lymphoma/22481079/1/files/39932589.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361939654.pdf","grobid_xml":"https://content.openalex.org/works/W4361939654.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2950334334","https://openalex.org/W2396270966","https://openalex.org/W3164387393","https://openalex.org/W4361947385","https://openalex.org/W2953768725","https://openalex.org/W2268151149","https://openalex.org/W2585215038","https://openalex.org/W2096082426","https://openalex.org/W2297917740","https://openalex.org/W2157749844"],"abstract_inverted_index":{"Plasma":[0],"cytokine":[1],"levels":[2],"of":[3],"LTCR":[4],"responders":[5],"compared":[6],"to":[7],"all":[8],"other":[9],"patients.":[10]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}